メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
富山大学 ホーム
日本語
English
ホーム
プロファイル
研究部門
設備
プロジェクト
研究成果
データセット
受賞
活動
授業
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
掛下 幸太
病院助教, 博士（医学） 富山大学 2023年2月
透析部
h-index
77
被引用数
6
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2020
2024
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(31)
類似のプロファイル
(6)
フィンガープリント
Kota Kakeshitaが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Keyphrases
Chronic Kidney Disease
100%
Nephrotic Syndrome
76%
Tolvaptan
65%
Aquaporin-2 (AQP2)
62%
Hemodialysis
60%
Cyclic Adenosine Monophosphate (cAMP)
49%
Prognostic Impact
46%
Hemodialysis Initiation
43%
Glomerulonephritis
43%
Collecting Duct
39%
Renal Disease
39%
Steroid Therapy
38%
Congestive Heart Failure
33%
IgA Nephropathy (IgAN)
33%
Older Men
33%
Intra-abdominal Bleeding
28%
Cholesterol Crystal Embolism
28%
Cryofibrinogen
28%
Membranous Nephropathy
28%
Sclerosing mucoepidermoid Carcinoma with Eosinophilia
28%
Kimura Disease
28%
Mucoepidermoid Carcinoma
28%
Vascular Endothelial Growth Factor Inhibitors
28%
Advanced Gastric Cancer
28%
Older Patients
28%
Parotid Gland
28%
Peritoneal Dialysis
28%
Gemella Morbillorum
28%
Crescentic Glomerulonephritis
28%
IgA2
28%
Mantle Cell Lymphoma
28%
Arginine Vasopressin
28%
Remote Dielectric Sensing
28%
Infective Endocarditis
28%
Focal Segmental Glomerulosclerosis
28%
Intravitreal Injection
28%
Goreisan
28%
Urine Volume
21%
Renal Impairment
21%
Heart Failure
18%
Renal Biopsy
18%
Kampo
18%
Home Care
17%
Aquaresis
16%
Hemodialysis Patients
15%
Refractoriness
15%
Malignant Hypertension
14%
Creatinine Index
14%
Takayasu Arteritis
14%
Nocturnal Blood Pressure
14%
Medicine and Dentistry
Hemodialysis
97%
Chronic Kidney Disease
93%
Nephrotic Syndrome
79%
Aquaporin 2
67%
Tolvaptan
67%
Glomerulonephritis
57%
Cyclic AMP
53%
Collecting Duct
40%
Steroid Therapy
38%
Immunoglobulin A Nephropathy
33%
Patient with Congestive Heart Failure
31%
Argipressin
28%
Angiolymphoid Hyperplasia with Eosinophilia
28%
Membranous Glomerulonephritis
28%
Mucoepidermoid Carcinoma
28%
Eosinophilia
28%
Vasculotropin Inhibitor
28%
Gemella morbillorum
28%
Abdominal Bleeding
28%
Parotid Gland
28%
Peritoneal Dialysis
28%
Embolization
28%
Mantle Cell Lymphoma
28%
Intravitreal Administration
28%
Infective Endocarditis
28%
Focal Segmental Glomerulosclerosis
28%
Congestive Heart Failure
28%
Abdominal Cancer
28%
Creatinine
24%
Renal Biopsy
24%
Combination Therapy
20%
Kampo
19%
Cancer
16%
Chemotherapy
15%
Primary Hyperaldosteronism
14%
Malignant Hypertension
14%
Takayasu's Arteritis
14%
Fanconi Syndrome
14%
Renal Tubular Acidosis
14%
Growth Differentiation Factor 15
14%
Xanthine Oxidase
14%
Kidney Transplantation
14%
Metabolic Alkalosis
14%
Neck Mass
14%
Geriatrics
14%
Lipid Storage
14%
Liquid Chromatography-Mass Spectrometry
14%
Glomerular Capillary
14%
Aflibercept
14%
Ascites
14%
Pharmacology, Toxicology and Pharmaceutical Science
Tolvaptan
79%
Congestive Heart Failure
75%
Aquaporin 2
63%
Chronic Kidney Failure
45%
Hemodialysis
43%
Nephrotic Syndrome
43%
Cyclic AMP
35%
Kampo Medicine (Drug)
32%
Glomerulonephritis
28%
Vasculotropin Inhibitor
28%
Argipressin
28%
Intravitreal Administration
28%
Focal Glomerulosclerosis
28%
Abdominal Cancer
28%
Combination Therapy
23%
Frailty
14%
Sodium Zirconium Cyclosilicate
14%
Growth Differentiation Factor 15
14%
Ascites
14%
Hyperkalemia
14%
Xanthine Oxidase
14%
Kidney Disease
14%
Aflibercept
14%
Prevalence
9%
Diuretic Therapy
9%
Brain Natriuretic Peptide
8%
Vasopressin
8%
Immobility
7%
Leg Edema
7%
Membranoproliferative Glomerulonephritis
7%
Hypoalbuminemia
7%
Electron Microscopy
7%
Oxaliplatin
7%
Chemotherapy
7%
Hematuria
7%
Proteinuria
7%
Rare Disease
7%
Remission
7%
Adenocarcinoma
7%
Oteracil Potassium
7%
Fibrinogen
7%
Fibronectin
7%
Tegafur
7%
Gimeracil
7%
Systemic Administration
7%
Disease
7%
Agents Acting on the Eye
7%
Kidney Injury
7%
Prospective Study
6%
Biological Marker
6%
